C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.

Saved in:
Bibliographic Details
Main Authors Pitzen, Jennifer, Gliedt, Micah James Evans, Semko, Christopher Michael, Wang, Gang, Lee, Julie Chu-Li, Burnett, G. Leslie, Kiss, Gert, Aggen, James Bradley, Gill, Adrian Liam, Thottumkara, Arun P, Mellem, Kevin T, Won, Walter
Format Patent
LanguageEnglish
Published 20.04.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
Bibliography:Application Number: US202016831579